Viewing Study NCT03302234


Ignite Creation Date: 2025-12-25 @ 2:31 AM
Ignite Modification Date: 2026-01-26 @ 5:00 PM
Study NCT ID: NCT03302234
Status: COMPLETED
Last Update Posted: 2023-09-26
First Post: 2017-09-26
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Non-Small-Cell Lung View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Programmed Cell Death Receptor 1 (PD-1) View
None Programmed Cell Death Receptor Ligand 1 (PD-L1) View
None Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) View
None PD1 View
None PD-1 View
None PDL1 View
None PD-L1 View
None CTLA4 View